FAE

Conner, United States
Conner, United States

Time filter

Source Type

News Article | May 19, 2017
Site: www.eurekalert.org

PHILADELPHIA -- Medical errors are a leading cause of death in the United States, with some research suggesting that errors can cause as many 250,000 fatalities each year. The medical community has made strides to normalize and encourage error disclosure for physicians and medical trainees in order to improve patient safety and health care outcomes, but these guidelines fall short when it comes to addressing the social psychology that influences how and when physicians and medical trainees disclose errors and how they manage the consequences of those errors. In a paper published this month in Medical Education authors Neha Vapiwala, MD, an associate professor of Radiation Oncology and vice chair of Education in the Perelman School of Medicine at the University of Pennsylvania and Jason Han, a fourth-year student in the Perelman School of Medicine, call for better education and training focused on the psychological challenges that coincide with errors and error disclosure in order to improve outcomes and reduce the number and severity of medical errors. "We must transform the culture of error disclosure in the medical community from one that is often punitive to one that is restorative and supportive," Vapiwala said. "And to do that, we must tend to the psychological challenges that medical professionals wrestle with when they face the possibility of disclosing an error." Initiatives such as the Disclosure, Apology, and Offer model have helped make moderate gains in creating a culture of transparency in health systems, but these efforts primarily focus on the legal and financial aspects of error disclosure and do not address other barriers, such as the fear, shame, and guilt that come with error disclosure. "Arguably, these psychological factors are harder to overcome, especially in this modern age of social media where health care providers can be reviewed and scrutinized in very public forums," Vapiwala said. "There is real concern that any little slip-up can live on the internet for the rest of someone's career." The authors identified two main cognitive biases that often hinder error disclosure: Fundamental Attribution Error (FAE), which is the tendency overestimate one's own role in a situation, and Forecasting Error (FE), the tendency to overestimate impact and duration of negative consequences while underestimating the ability to recover from those circumstances. For example, if an error led to a patient injury, the physician might initially overstate his own role in that error rather than examine any systematic reasons for why that error occurred. Secondly, he may then also overestimate the long-term consequences or recovery time for that patient, leading to feelings of both self-blame and exaggerated doom, both of which damage the physician-patient relationship and may impede a care provider from reporting the error. "Overcoming these biases is akin to suppressing a reflex. It requires self-awareness, practice, and most importantly, education and training," Vapiwala said. Looking at other fields that have high-stake consequences when an error occurs, such as the airline industry, the authors offer several strategies to overcome these patterns of thought, utilizing elements of social psychology to transform the current culture of error disclosure. Recommendations include incorporating standardized patients (SPs), actors who simulate patients, not only to "practice" difficult patient encounters, but also to help model interactions with family members, peers, and administrators in order to teach various behavior and coping mechanisms. SPs have been proven to effectively mimic the psychosocial elements of error disclosure, including profound guilt, feelings of ineptitude, and fear of repercussions. Virtual reality (VR) is another tool that can offer immersive and realistic technology to supplement traditional curricula, while also offering tremendous scalability at a lower cost than SPs. The authors cite an example of a recent VR exercise which allowed viewers to experience the perspective of a 12-year Syrian refugee to incite more compassion and understanding. While VR medical content doesn't currently exist, it is on the horizon for many medical trainees and professions. However, both SP and VR do have limitations, as the users ultimately know that the scenario is simulated. "Standardized patients and other simulated scenarios provide an excellent foundation, but until you are put into a real-world situation and forced to confront your mistake and its potential consequences, you can't truly understand the psychosocial challenges," Han said. Finally, the authors recommend implementing a professional standard for trainees, including a formal evaluation of the skills needed to disclose and cope with medical errors. This standard would further normalize error disclosure and make it a common practice among physicians and trainees. The authors conclude that the primary change will need to be cultural, not just among trainees, but at every level of medical practice, in order to successfully pivot away from the current stigma related to error disclosure. "Administrators must make a shift from asking 'who is at fault' to asking 'why' and 'how' did a situation occur, creating a culture that embraces error disclosure and seeks to solve the many systematic factors that lead to an error in the first place. This approach will not only normalize error disclosures but also help us better understand why they happen so we can prevent more of them in the future," Vapiwala said. Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.


News Article | May 19, 2017
Site: www.sciencedaily.com

A new study suggests that fetal alcohol exposure (FAE) reduces the taste system's responsiveness to the bitter flavor and burning sensation of many varieties of alcoholic beverages. These factors make alcohol unappealing to some people, but, for reasons that are unclear, are less of a deterrent in young people exposed to alcohol before birth. The study is published ahead of print in the Journal of Neurophysiology. Previous studies have found that FAE reduces the sense of smell of alcohol and that teens exposed to alcohol in utero have an increased risk of alcohol abuse. "It is possible that FAE makes the flavor of alcohol less aversive. This could increase the risk of adolescents experimenting with alcohol and developing a pattern of abuse," the research team wrote. The researchers compared oral sensory responses to alcohol and its flavor components, namely bitter (quinine), sweet (sugar) and burning and irritation (capsaicin and mustard oil) in an adolescent rat model of FAE and control rats. They recorded responses from two nerves that convey input about taste to the brain and one nerve that conveys input about oral burning and irritation to the brain (trigeminal nerve). Compared with control rats, the taste nerves of FAE rats showed weaker responses to alcohol and quinine taste during adolescence. The reduced responses of these taste nerves to quinine persisted into adulthood, implying lifelong alterations in bitter taste function. The FAE rats also had reduced trigeminal responses to alcohol, capsaicin and mustard oil during adolescence. "Our results demonstrate that FAE reprograms development of the rat's peripheral taste and trigeminal systems," the research team wrote. More study is needed to determine exactly how alcohol exposure before birth reprograms different parts of the nervous system, the researchers noted. The article, "Fetal alcohol exposure reduces responsiveness of taste nerves and trigeminal chemosensory neurons to ethanol and its flavor components," is published ahead of print in the Journal of Neurophysiology.


News Article | May 19, 2017
Site: www.sciencedaily.com

Medical errors are a leading cause of death in the United States, with some research suggesting that errors can cause as many 250,000 fatalities each year. The medical community has made strides to normalize and encourage error disclosure for physicians and medical trainees in order to improve patient safety and health care outcomes, but these guidelines fall short when it comes to addressing the social psychology that influences how and when physicians and medical trainees disclose errors and how they manage the consequences of those errors. In a paper published this month in Medical Education authors Neha Vapiwala, MD, an associate professor of Radiation Oncology and vice chair of Education in the Perelman School of Medicine at the University of Pennsylvania and Jason Han, a fourth-year student in the Perelman School of Medicine, call for better education and training focused on the psychological challenges that coincide with errors and error disclosure in order to improve outcomes and reduce the number and severity of medical errors. "We must transform the culture of error disclosure in the medical community from one that is often punitive to one that is restorative and supportive," Vapiwala said. "And to do that, we must tend to the psychological challenges that medical professionals wrestle with when they face the possibility of disclosing an error." Initiatives such as the Disclosure, Apology, and Offer model have helped make moderate gains in creating a culture of transparency in health systems, but these efforts primarily focus on the legal and financial aspects of error disclosure and do not address other barriers, such as the fear, shame, and guilt that come with error disclosure. "Arguably, these psychological factors are harder to overcome, especially in this modern age of social media where health care providers can be reviewed and scrutinized in very public forums," Vapiwala said. "There is real concern that any little slip-up can live on the internet for the rest of someone's career." The authors identified two main cognitive biases that often hinder error disclosure: Fundamental Attribution Error (FAE), which is the tendency overestimate one's own role in a situation, and Forecasting Error (FE), the tendency to overestimate impact and duration of negative consequences while underestimating the ability to recover from those circumstances. For example, if an error led to a patient injury, the physician might initially overstate his own role in that error rather than examine any systematic reasons for why that error occurred. Secondly, he may then also overestimate the long-term consequences or recovery time for that patient, leading to feelings of both self-blame and exaggerated doom, both of which damage the physician-patient relationship and may impede a care provider from reporting the error. "Overcoming these biases is akin to suppressing a reflex. It requires self-awareness, practice, and most importantly, education and training," Vapiwala said. Looking at other fields that have high-stake consequences when an error occurs, such as the airline industry, the authors offer several strategies to overcome these patterns of thought, utilizing elements of social psychology to transform the current culture of error disclosure. Recommendations include incorporating standardized patients (SPs), actors who simulate patients, not only to "practice" difficult patient encounters, but also to help model interactions with family members, peers, and administrators in order to teach various behavior and coping mechanisms. SPs have been proven to effectively mimic the psychosocial elements of error disclosure, including profound guilt, feelings of ineptitude, and fear of repercussions. Virtual reality (VR) is another tool that can offer immersive and realistic technology to supplement traditional curricula, while also offering tremendous scalability at a lower cost than SPs. The authors cite an example of a recent VR exercise which allowed viewers to experience the perspective of a 12-year Syrian refugee to incite more compassion and understanding. While VR medical content doesn't currently exist, it is on the horizon for many medical trainees and professions. However, both SP and VR do have limitations, as the users ultimately know that the scenario is simulated. "Standardized patients and other simulated scenarios provide an excellent foundation, but until you are put into a real-world situation and forced to confront your mistake and its potential consequences, you can't truly understand the psychosocial challenges," Han said. Finally, the authors recommend implementing a professional standard for trainees, including a formal evaluation of the skills needed to disclose and cope with medical errors. This standard would further normalize error disclosure and make it a common practice among physicians and trainees. The authors conclude that the primary change will need to be cultural, not just among trainees, but at every level of medical practice, in order to successfully pivot away from the current stigma related to error disclosure. "Administrators must make a shift from asking 'who is at fault' to asking 'why' and 'how' did a situation occur, creating a culture that embraces error disclosure and seeks to solve the many systematic factors that lead to an error in the first place. This approach will not only normalize error disclosures but also help us better understand why they happen so we can prevent more of them in the future," Vapiwala said.


SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA; NO PARA LOS MEDIOS SUIZOS/AUSTRIACOS/ESTADOUNIDENSES Zebinix® (acetato de eslicarbazepina) ofrece una elevada tasa de retención, reducción de la frecuencia de las crisis y ausencia de crisis con un perfil de efectos adversos favorable y una mejor impresión clínica global de cambio (CGI-C) y gravedad (CGI-S), cuando se utiliza como terapia adyuvante en personas con crisis (focales) de inicio parcial con o sin generalización secundaria, de acuerdo con el estudio ESLADOBA, presentado hoy en la Reunión Anual de la Sociedad Americana de Epilepsia (AES) celebrada en Houston, EE. UU.[1] El acetato de eslicarbazepina está indicado en la Unión Europea como terapia adyuvante en pacientes adultos que presentan crisis de inicio parcial, con o sin generalización secundaria.[2] El estudio de cohortes, multicéntrico, prospectivo, no intervencionista y de dos años de duración incluyó a 52 pacientes (≥18 años), de 12 servicios de neurología de Portugal, con crisis (focales) de inicio parcial no suficientemente controladas con un fármaco antiepiléptico (FAE) y que habían iniciado tratamiento con acetato de eslicarbazepina de forma adyuvante. El criterio de valoración principal fue la tasa de retención, definida como el porcentaje de pacientes tratados con acetato de eslicarbazepina que continuaron con el tratamiento hasta el final del periodo de seguimiento. Los criterios de valoración secundarios incluyeron el porcentaje de respondedores (pacientes con una reducción de al menos un 50% en la frecuencia de las crisis, en comparación con el inicio), el porcentaje de pacientes libres de crisis y el cambio en la frecuencia de las crisis parciales con o sin generalización secundaria.[1] En el estudio ESLADOBA, se observó un porcentaje de retención del 73,0% (IC del 95%, 61,0-85,2). Los porcentajes de respondedores y de pacientes libres de crisis fueron del 71,1% (IC del 95%, 56,7-85,5) y del 39,5% (IC del 95%, 24,0-55,0) respectivamente. El porcentaje de pacientes libres de crisis observado en el grupo de crisis con generalización secundaria fue del 94,7% en la evaluación final. La mediana de reducción relativa en la frecuencia de las crisis entre el inicio y la evaluación final fue del 82,2% (con un tiempo medio entre las evaluaciones inicial y final de 7,8 meses).[1] Se redujo la gravedad de la epilepsia en un 42,1% de los pacientes, y el 73,6% de los pacientes «mejoraron mucho» o «mejoraron muchísimo», sin ningún caso en el que se considerase que la epilepsia empeoró, de acuerdo con la impresión clínica global de cambio (GCI-C) y de gravedad (CGI-S), registrada por neurólogos. En este estudio, el 23,1% (n=12) de los pacientes sufrió al menos un efecto adverso, el 19,2% (n=10) presentó al menos un EA que se consideró relacionado con el fármaco del estudio y un 3,9% (n=2) padeció al menos un efecto adverso grave. La mayor parte de los efectos adversos se clasificaron como de intensidad leve o moderada (n=14), y (n=9) fueron clasificados como graves.[1] Por último, 5 pacientes se retiraron del estudio debido a efectos adversos. «El estudio ESLADOBA demuestra que la terapia adyuvante con acetato de eslicarbazepina administrado una vez al día aportó buenas tasas de retención y ofrece una reducción significativa de la frecuencia de las crisis en pacientes con crisis de inicio parcial no suficientemente controladas con monoterapia», comenta el Dr. João Chaves, Neurólogo, Hospital Santo Antonio, Centro Hospitalar do Porto. «Los datos registrados en la práctica clínica rutinaria resultan cruciales para ayudarnos a saber cómo funciona el tratamiento en el mundo real. Estos hallazgos sugieren un control efectivo de las crisis y una tolerabilidad favorable con la terapia adyuvante con acetato de eslicarbazepina en este entorno", Patrício Soares-da-Silva, Director de Investigación y Desarrollo, Bial, Oporto, Portugal. «Estos datos subrayan nuestro compromiso por apoyar a las personas con epilepsia para que puedan disfrutar de mejores tratamientos y vivir vidas plenas. Estos datos son prometedores y permitirán que el acetato de eslicarbazepina continúe desempeñando una función importante en el tratamiento de la epilepsia para las miles de personas de Europa que viven con esta enfermedad», comenta Neil West, Vicepresidente, Unidad de Negocio de Neurología Global, Eisai. El acetato de eslicarbazepina es un bloqueante de los canales de sodio regulados por voltaje. Actúa selectivamente en el estado inactivado lento del canal iónico de sodio, (el cual participa en la patogénesis de la epilepsia), evitando que vuelva al estado activado, lo que reduce la activación neuronal repetitiva.[3] Además, el acetato de eslicarbazepina no inhibe la salida de potasio, lo que puede reducir la posibilidad de que se produzcan más activaciones neuronales.[4] La eficacia del acetato de eslicarbazepina se demostró en un estudio en fase II inicial de prueba de concepto[5] y en tres estudios posteriores en fase III, aleatorizados y controlados con placebo, en los que participaron 1049 pacientes con crisis de inicio parcial refractarias.[6],[7],[8] En Europa y Rusia, el acetato de eslicarbazepina lo comercializa actualmente Bial y Eisai Europe Limited, una filial europea de Eisai Co., Ltd con licencia cedida por Bial bajo el nombre comercial de Zebinix® o Exalief®. En los Estados Unidos y Canadá el acetato de eslicarbazepina (nombre comercial Aptiom®) lo comercializa Sunovion Pharmaceuticals Inc., bajo una licencia exclusiva de Bial. La epilepsia es uno de los trastornos neurológicos más frecuentes en el mundo, que afecta a aproximadamente seis millones de personas en Europa y alrededor de cincuenta millones en todo el mundo.[9],[10] La epilepsia es un trastorno crónico del cerebro que afecta a gente de todas las edades. Se caracteriza por una activación anormal de los impulsos neuronales, que provoca las crisis. Éstas pueden variar según su gravedad, desde breves lapsos de atención o sacudidas musculares, hasta convulsiones severas y prolongadas. En función de su tipo, las crisis pueden limitarse a una parte del cuerpo o pueden implicar al cuerpo entero. Además, estas crisis también pueden variar en cuanto a su frecuencia, desde menos de una al año a varias al día. La epilepsia tiene muchas causas posibles, pero con frecuencia la causa es desconocida. Fundada en 1924, BIAL es una compañía farmacéutica internacional cuya misión es descubrir, desarrollar y proporcionar soluciones terapéuticas en el área de la salud. En las últimas décadas, BIAL se ha centrado en la calidad, la innovación y la internacionalización. Socia de elección para numerosas compañías, Bial muestra un compromiso sólido con la innovación terapéutica, invirtiendo más del 20% de su volumen de negocios en Investigación y Desarrollo (I+D) cada año. Bial ha creado un ambicioso programa de I+D centrado en la neurociencia y cardiovascular y en la inmunoterapia contra las alergias. La compañía espera presentar más vacunas y medicamentos nuevos al mercado en los próximos años, reforzando su posición mundial y cumpliendo el objetivo de la compañía de «Preocuparse por su salud». Eisai Co., Ltd. es una compañía farmacéutica líder mundial basada en la investigación y el desarrollo que tiene su sede en Japón. Definimos nuestra misión corporativa como "pensar ante todo en los pacientes y en sus familias y mejorar los beneficios que proporciona la asistencia sanitaria", a lo que llamamos filosofía human health care (hhc). Los más de 10.000 empleados que integran nuestra red global de instalaciones de I+D, centros de fabricación y filiales de comercialización trabajan por materializar nuestra filosofía hhc a través de productos innovadores en diferentes áreas terapéuticas que presentan grandes necesidades médicas no cubiertas, incluidas la oncología y la neurología. Como compañía farmacéutica global, nuestra misión se dirige a pacientes de todo el mundo, mediante nuestra inversión y participación en iniciativas basadas en la colaboración que buscan mejorar el acceso a los medicamentos en los países en desarrollo y emergentes.


News Article | November 18, 2015
Site: www.scientificcomputing.com

In advance of the Modeling, Simulation and Crash Testing of Automotive Lightweight Materials Congress — a congress encompassing cost-effective modeling, crash simulation and lifecycle prediction for lightweight materials and composites that will take place January 26-27, 2016, in Detroit, MI — presenters Steven Sheng, a formability engineer at General Motors and Xinran Xiao, a professor of mechanical engineering at Michigan State University, offer a few insights on their upcoming talks. Q: Dr. Sheng, your presentation at the Crash Simulation Summit will look at the question of predicting fracture in warm forming magnesium alloys. Could you briefly outline the concept for readers and what new knowledge they will be able to take away with them? Steven Sheng: A method to represent forming limit for warm forming Mg alloy sheet material will be presented.  In the method, the strain rate and temperature effect is presented concisely by a single parameter of Zener-Hollomon parameter. Thus, the forming limit can be represented as a Forming Limit Surface. Traditionally, Forming Limit Curves (FLCs) are used to identify fracture/necking failure in sheet metal forming. At elevated temperatures, the Mg alloys exhibit strong rate sensitivity and thus many FLCs are needed to represent different forming conditions. Those FLCs are not only costly to be obtained but also inconvenient to be used in FEM simulations.  In this presentation, a new method to represent forming limit for warm forming Mg alloy sheet material will be introduced. In the method, the strain rate and temperature effect is presented concisely by a single parameter of Zener-Hollomon parameter. Thus, the forming limit can be represented as a Forming Limit Surface. Since only one surface is needed, the method could reduce the efforts of laboratory testing and provide a convenient tool in the development of thermal forming processes. The usefulness of the Forming Limit Surface is demonstrated by predicting fracture in warm forming magnesium alloy AZ31B in isothermal conical cup test and non-isothermal round cup draw test. Q: What do you see as the most important hurdles to overcome in implementing CAE and FAE technologies for safety testing of lightweight materials? What optimizations need to be implemented? Sheng: The accuracy of simulation result, which is affected by many factors, such as material modeling, mesh quality, accuracy of algorithm etceera. The product development can be regarded as a multi-objective optimization problem. Thus, a multi-objective optimization solver, which can be adapted with different CAE solvers, is needed. Q: What are some of the potential applications and implications of improved material models and more accurate safety simulations to the manufacture of lightweight vehicles? Sheng: The accuracy of CAE prediction depends on material modeling. Accurate material models are critical for any CAE analysis. Q: Professor Xiao, your presentation at the Crash Simulation Summit will look at the question of modeling thin-walled composites for crash simulation. Could you briefly outline the concept for readers and what new knowledge they will be able to take away with them? Xinran Xiao: Thin-walled tubes represent the front rails, which are the primary energy-absorbing structures in vehicles. In frontal impact, the front rails are subjected to axial crash load. Axial crash of tubes is the benchmark problem to gauge the capability of crash simulations. The axial crash simulation of composite tubes is a very challenging problem. Composite tubes can absorb twice or more energy than steel rails of the same weight. The superior energy absorption of composites is attributed to the extensive damage and failure of the materials. To simulate the behavior of composites with damage and failure, however, is difficult. Normally, the constitutive models are valid to the point where material reaches its peak-load carrying ability. They are not adequate to describe the behavior of materials with significant damage. In early days, to match the simulations with experimental results, the analysts had to adjust a number of parameters. The problem is that a set of parameters which is suitable for one geometry would not work for others. There was no prediction. After having tested these material models myself, I realized that the lack of consideration of irreversible strains in continue damage mechanics based model is a major problem in axial crash simulations. On the other hand, with the exception of few, most vehicle structures will not be subjected to axial loading. The inability of predicting axial crash should not prevent the use of composites in these applications. In my presentation, I will discuss the requirements for composite material models for different types of vehicle structures. I will also present the key developments in axial crash simulation of composite tubes. We are working on coupled damage-plasticity models for composites. The improved material models together with a new shell-beam method for thin-walled structures have resulted in promising improvement in axial crash simulations of composite tubes. Q: What do you see as the most important hurdles to overcome in implementing CAE and FEA technologies for safety testing of lightweight materials? What optimizations need to be implemented? Xiao: With high fidelity FEA simulations, different design options can be evaluated through virtual testing before they are built. Virtual design and validation is critical to car makers. If the simulation technology is not ready for a material, extra tests will have to be conducted. This is a hurdle for the use of composites in crash critical components. For crash simulations, we still have some gaps comparing to metallic materials. As mentioned in the response to the 1st question, we need to differentiate the types of vehicle structures. In many cases, we can bridge the gaps with the existing technology. I am not sure about “What optimizations need to be implemented?” Do you talk about optimization as a topic or optimization within the context of material modeling? Indeed, it was referring to optimization within the context of material modeling. Parameter optimization is a powerful tool. The constitutive models for crash simulations inevitably have many parameters. Some of them are difficult to measure. If we have experimental results covering enough load cases, parameter optimization may help us to get the set of parameters which provides best correlations for the load cases tested. I have done some work several years ago. It is effective. On the other hand, one must know that these values are not necessarily valid for a new load case. Q: What are some of the potential applications and implications of improved material models and more accurate safety simulations to the manufacture of lightweight vehicles? Xiao: FEA simulations have changed the landscape of automotive design. The car manufacturer will not turn back the wheel to a testing-intensive design procedure, as it was before the computer age. To increase the use of composites in crash critical structures, we have to be able to predict the crashworthiness of the structure as we do for metal parts. Good material models, robust and accurate safety simulations are critical to vehicle lightweighting. As I mentioned earlier, the technology for crash simulation of composite structures has improved a lot. Ideally, these new developments need to be examined carefully through some coordinated effort. Individual teams can only carry the research to a certain extent. It up to the users/automotive industry to continue. I think this conference provides a good forum for such discussions. Q: Which presentation/panel discussion are you especially excited about during the Lightweight Vehicle Interiors summit 2016? Xiao: All panels are very interesting.  In addition to composite modeling, I am also interested in modeling of multi-material joining. Modeling joints is another challenging topic. I worked on modeling of adhesively bonded automotive structures in the past. In recent years, we worked on simulations of metal cutting using constitutive models developed in-house, and we developed a new test to obtain the critical model parameters. We were able to show that metal cutting is predictable with these efforts. If there is an opportunity, I would like to participate the modeling of multi-material joining.


News Article | February 24, 2017
Site: www.prweb.com

Qolture®, one of America’s most distinguished furniture retailers, is proud to announce its new partnership with Furniture Assembly Experts® (FAE), a renowned East Coast authority in furniture assemblage. The collaboration grants Qolture clients who reside in Washington, D.C., Maryland, and Northern Virginia the ability to bundle FAE’s assembly service with their online purchases at checkout, seamlessly streamlining furniture shopping and setup. Discounted rates range from 5% to 10% depending on the size and type of furnishing. “Assembling furniture is a time consuming and frustrating process for people who lead busy lives,” notes Karl Sutton, Qolture’s CEO. “We at Qolture feel confident that Furniture Assembly Experts is a reputable company that will satisfy our customers' furniture assembly needs in a timely manner.” The new offering is a terrific supplement to Qolture’s worry-free shipping, which ensures all orders are delivered via trusted local partners and comes at no charge for all orders over $99. Customers unsatisfied with their merchandise can return all non-damaged products—including sale items—within 90 days of purchase. Shipping charges incurred in relation with the return of a product are also refundable. “We are very excited to partner with Qolture and service its customers,” says FAE’s founder and CEO, Dave Song. “Both companies focus on quality service and products, so we believe this partnership is a good fit and will improve the reputations of our separate brands.” About Furniture Assembly Experts Established by Dave Song in 2011, FAE specializes in the on-site building, dismantling, and installation of premium furniture. Based in Lanham, MD, the company touts a team of highly skilled technicians capable of tackling all flat-pack and ready-to-assemble pieces intended for both indoor and outdoor use. The BBB-accredited business, which boasts an A+ Rating, offers same-day and next-day services and guarantees first-rate workmanship backed by a 30-day warranty on all installation jobs. About Qolture The premier online destination for modern home furnishings, Qolture® showcases a comprehensive collection of contemporary furnishings and accessories sourced from all over the world—from eco-friendly bookcases to sumptuous sofas to vintage wall art. Carefully curated by an elite network of home décor connoisseurs, the Las Vegas-based retailer’s unique selection of fine-quality products is constantly changing—ensuring that there are always fresh pieces available to suit every room, style, and season. For interior design inspiration—from tips for creating a dashing dining room to tricks for transforming your home office into a stylish workspace—click here to visit Qolture’s blog.


This report studies sales (consumption) of Thickness Measuring devices in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Allied Dart systems Ltd FAE Srl GERBER  GreCon Kurschat GmbH Labthink Instruments Co., Ltd.  LAP GmbH MITUTOYO NDC Technologies PLAST-CONTROL GmbH  ROLAND ELECTRONIC  Sikora AG TRIOPTICS WalthMac Measurement & Control Technology Co., Ltd. View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/europe-thickness-measuring-devices-market-report-to-2021 Market Segment by Regions, this report splits Europe into several key Regions, with sales (consumption), revenue, market share and growth rate of Thickness Measuring devices in these regions, from 2011 to 2021 (forecast), like Germany France UK Italy Spain Russia Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Laser Ultrasonic Capacitive Others Split by applications, this report focuses on sales, market share and growth rate of Thickness Measuring devices in each application, can be divided into Cutting edge Extrusion lines Pipes Others 1 Thickness Measuring devices Overview 1.1 Product Overview and Scope of Thickness Measuring devices 1.2 Classification of Thickness Measuring devices 1.2.1 Laser 1.2.2 Ultrasonic 1.2.3 Capacitive 1.2.4 Others 1.3 Applications of Thickness Measuring devices 1.3.1 Cutting edge 1.3.2 Extrusion lines 1.3.3 Pipes 1.3.4 Others 1.4 Thickness Measuring devices Market by Regions 1.4.1 Germany Status and Prospect (2011-2021) 1.4.2 France Status and Prospect (2011-2021) 1.4.3 UK Status and Prospect (2011-2021) 1.4.4 Italy Status and Prospect (2011-2021) 1.4.5 Spain Status and Prospect (2011-2021) 1.4.6 Russia Status and Prospect (2011-2021) 1.5 Europe Market Size (Value and Volume) of Thickness Measuring devices (2011-2021) 1.5.1 Europe Thickness Measuring devices Sales, Revenue and Price (2011-2021) 1.5.2 Europe Thickness Measuring devices Sales and Growth Rate (2011-2021) 1.5.3 Europe Thickness Measuring devices Revenue and Growth Rate (2011-2021) 9 Europe Thickness Measuring devices Manufacturers Analysis 9.1 Allied 9.1.1 Company Basic Information,Manufacturing Base and Competitors 9.1.2 Thickness Measuring devices Product Type and Technology 9.1.2.1 Type I 9.1.2.2 Type II 9.1.3 Thickness Measuring devices Sales, Revenue, Price of Allied (2015 and 2016) 9.2 Dart systems Ltd 9.2.1 Company Basic Information,Manufacturing Base and Competitors 9.2.2 Thickness Measuring devices Product Type and Technology 9.2.2.1 Type I 9.2.2.2 Type II 9.2.3 Thickness Measuring devices Sales, Revenue, Price of Dart systems Ltd (2015 and 2016) 9.3 FAE Srl 9.3.1 Company Basic Information,Manufacturing Base and Competitors 9.3.2 Thickness Measuring devices Product Type and Technology 9.3.2.1 Type I 9.3.2.2 Type II 9.3.3 Thickness Measuring devices Sales, Revenue, Price of FAE Srl (2015 and 2016) 9.4 GERBER  9.4.1 Company Basic Information,Manufacturing Base and Competitors 9.4.2 Thickness Measuring devices Product Type and Technology 9.4.2.1 Type I 9.4.2.2 Type II 9.4.3 Thickness Measuring devices Sales, Revenue, Price of GERBER  (2015 and 2016) 9.5 GreCon 9.5.1 Company Basic Information,Manufacturing Base and Competitors 9.5.2 Thickness Measuring devices Product Type and Technology 9.5.2.1 Type I 9.5.2.2 Type II 9.5.3 Thickness Measuring devices Sales, Revenue, Price of GreCon (2015 and 2016) 9.6 Kurschat GmbH 9.6.1 Company Basic Information,Manufacturing Base and Competitors 9.6.2 Thickness Measuring devices Product Type and Technology 9.6.2.1 Type I 9.6.2.2 Type II 9.6.3 Thickness Measuring devices Sales, Revenue, Price of Kurschat GmbH (2015 and 2016) 9.7 Labthink Instruments Co., Ltd.  9.7.1 Company Basic Information,Manufacturing Base and Competitors 9.7.2 Thickness Measuring devices Product Type and Technology 9.7.2.1 Type I 9.7.2.2 Type II 9.7.3 Thickness Measuring devices Sales, Revenue, Price of Labthink Instruments Co., Ltd.  (2015 and 2016) 9.8 LAP GmbH 9.8.1 Company Basic Information,Manufacturing Base and Competitors 9.8.2 Thickness Measuring devices Product Type and Technology 9.8.2.1 Type I 9.8.2.2 Type II 9.8.3 Thickness Measuring devices Sales, Revenue, Price of LAP GmbH (2015 and 2016) 9.9 MITUTOYO 9.9.1 Company Basic Information,Manufacturing Base and Competitors 9.9.2 Thickness Measuring devices Product Type and Technology 9.9.2.1 Type I 9.9.2.2 Type II 9.9.3 Thickness Measuring devices Sales, Revenue, Price of MITUTOYO (2015 and 2016) 9.10 NDC Technologies 9.10.1 Company Basic Information,Manufacturing Base and Competitors 9.10.2 Thickness Measuring devices Product Type and Technology 9.10.2.1 Type I 9.10.2.2 Type II 9.10.3 Thickness Measuring devices Sales, Revenue, Price of NDC Technologies (2015 and 2016) 9.11 PLAST-CONTROL GmbH  9.11.1 Company Basic Information,Manufacturing Base and Competitors 9.11.2 Thickness Measuring devices Product Type and Technology 9.11.2.1 Type I 9.11.2.2 Type II 9.11.3 Thickness Measuring devices Sales, Revenue, Price of PLAST-CONTROL GmbH  (2015 and 2016) 9.12 ROLAND ELECTRONIC  9.12.1 Company Basic Information,Manufacturing Base and Competitors 9.12.2 Thickness Measuring devices Product Type and Technology 9.12.2.1 Type I 9.12.2.2 Type II 9.12.3 Thickness Measuring devices Sales, Revenue, Price of ROLAND ELECTRONIC  (2015 and 2016) 9.13 Sikora AG 9.13.1 Company Basic Information,Manufacturing Base and Competitors 9.13.2 Thickness Measuring devices Product Type and Technology 9.13.2.1 Type I 9.13.2.2 Type II 9.13.3 Thickness Measuring devices Sales, Revenue, Price of Sikora AG (2015 and 2016) 9.14 TRIOPTICS 9.14.1 Company Basic Information,Manufacturing Base and Competitors 9.14.2 Thickness Measuring devices Product Type and Technology 9.14.2.1 Type I 9.14.2.2 Type II 9.14.3 Thickness Measuring devices Sales, Revenue, Price of TRIOPTICS (2015 and 2016) 9.15 WalthMac Measurement & Control Technology Co., Ltd. 9.15.1 Company Basic Information,Manufacturing Base and Competitors 9.15.2 Thickness Measuring devices Product Type and Technology 9.15.2.1 Type I 9.15.2.2 Type II 9.15.3 Thickness Measuring devices Sales, Revenue, Price of WalthMac Measurement & Control Technology Co., Ltd. (2015 and 2016) Global QYResearch ( http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


Fycompa è un nuovo trattamento antiepilettico in monosomministrazione giornaliera disponibile e rimborsato dal SSN Italiano dal mese di maggio 2015. Fycompa, nell'indicazione trattamento aggiuntivo di crisi epilettiche parziali, con o senza generalizzazione secondaria, in pazienti adulti e adolescenti dai 12 anni di età affetti da epilessia, è già una realtà nell'armamentario terapeutico dello Specialista Neurologo ed ha contribuito a migliorare il benessere di numerosi pazienti. Le crisi PGTC iniziano con una perdita di coscienza e un'improvvisa contrazione muscolare che può causare la caduta della persona (fase tonica). A questa fase seguono delle violente crisi convulsive (fase clonica) fino a quando i muscoli infine si rilassano.[8] Il rischio di lesioni, fratture ossee, trauma cranici e ustioni, aumenta in funzione della frequenza delle crisi generalizzate[9] e dell'età di insorgenza della malattia.[10] La frequenza delle crisi generalizzate aumenta inoltre il rischio di morte improvvisa inaspettata in epilessia (Sudden Unexpected Death in Epilepsy), che si stima sia responsabile di numerosi decessi anche in Italia.[11] L'efficacia di Fycompa come terapia aggiuntiva di crisi PGTC, in pazienti adulti e adolescenti dai 12 anni di età affetti da IGE) è stata dimostrata in uno studio multicentrico, randomizzato, in doppio cieco, controllato verso placebo (studio 332). I pazienti eleggibili in terapia con una dose stabile di 1‑3 FAE che manifestavano almeno 3 crisi PGTC durante il periodo basale di 8 settimane sono stati randomizzati al trattamento con Fycompa o placebo. La popolazione comprendeva 164 pazienti (Fycompa n=82, placebo n=82). I pazienti sono stati titolati nell'arco di quattro settimane a una dose target di 8 mg/die o alla dose massima tollerata e trattati per ulteriori 13 settimane all'ultimo livello di dose raggiunto al termine del periodo di titolazione. I risultati dello studio 332 hanno evidenziato che: "Garantire l'accesso al nostro trattamento capostipite della classe di farmaci antiepilettici perampanel nella nuova indicazione delle crisi tonico-cloniche generalizzate primarie nell'epilessia generalizzata idiopatica rappresenta il passo successivo naturale dopo l'estensione della sua disponibilità, a partire dall'anno scorso, alle persone che soffrono di crisi (focali) a esordio parziale. Inoltre rafforza la missione human health care di Eisai, compreso l'impegno nei confronti dell'epilessia nel suo senso più ampio e verso il miglioramento degli esiti per i pazienti e le loro famiglie", ha spiegato Giuseppe Lo Presti, Direttore Neurology Business Group, Eisai Italia. Lo sviluppo continuo di perampanel conferma la missione di Eisai nel settore human health care (hhc), l'impegno dell'azienda a sviluppare soluzioni innovative per la prevenzione e la cura delle malattie e per l'assistenza sanitaria e il benessere delle persone in tutto il mondo. Eisai opera nel settore terapeutico dell'epilessia dedicandosi a soddisfare le esigenze terapeutiche dei pazienti affetti da epilessia e delle loro famiglie. Eisai è orgogliosa di essere l'azienda che commercializza il più alto numero di prodotti per l'epilessia nell'area EMEA. Perampanel ha mostrato efficacia ed è indicato per il trattamento aggiuntivo delle crisi a esordio parziale con o senza generalizzazione secondaria, in pazienti adulti e adolescenti epilettici di età pari o superiore a 12 anni e per il trattamento aggiuntivo delle crisi tonico-cloniche generalizzate primarie (PGTC) in pazienti adulti e adolescenti a partire dai 12 anni di età con epilessia generalizzata idiopatica.[1] L'epilessia è una delle patologie neurologiche più comuni al mondo e colpisce circa 6 milioni di pazienti in Europa; si stima che al mondo le persone affette da questa patologia siano 50 milioni.[12] Si tratta di un insieme di sindromi con molte possibili cause ma la cui causa è spesso sconosciuta. L'epilessia è un disturbo neurologico che colpisce persone di tutte le età. È caratterizzata da scariche anomale di impulsi delle cellule nervose nel cervello che causano la comparsa di crisi epilettiche. Le crisi epilettiche possono variare in gravità: da brevi intervalli di attenzione o spasmi dei muscoli, a crisi gravi e prolungate. A seconda del tipo, le crisi possono essere limitate a una parte del corpo o possono essere generalizzate e coinvolgere tutto il corpo. Le crisi epilettiche possono anche variare per frequenza: da meno di una all'anno a diverse al giorno. Nella maggior parte dei pazienti affetti da epilessia generalizzata idiopatica, una crisi PGTC iniziano con la possibile presenza di aura, seguita da rigidità muscolare. Questo porta a una violenta contrazione muscolare (fase clonica) e alla perdita di coscienza. Trattandosi di eventi molto gravi, le crisi sono ritenute un grosso impedimento nella vita quotidiana delle persone che ne sono colpite. Sebbene una crisi duri generalmente solo qualche minuto, il paziente avvertirà una sensazione di confusione o sonnolenza per un breve periodo prima di tornare a sentirsi bene.[13] Le crisi PGTC possono anche determinare un rischio di lesione[10] e di morte improvvisa inspiegabile in epilessia (SUDEP).[12] Eisai Co., Ltd è una casa farmaceutica leader a livello mondiale nel settore Ricerca e Sviluppo con sede centrale in Giappone. Delinea come missione aziendale l'impegno di "dare priorità ai pazienti e alle famiglie e incrementare i benefici per la salute" definita da Eisai stessa la filosofia della human health care (hhc). Con oltre 10.000 dipendenti operativi nella rete mondiale di siti di R&S, siti di produzione e consociate addette alla commercializzazione, ci impegniamo a mettere in pratica la nostra filosofia hhc offrendo prodotti innovativi in diverse aree terapeutiche in cui esistono molteplici esigenze non soddisfatte, tra cui l'oncologia e la neurologia.


Miguel E.K.,FAE
Electronic Products | Year: 2013

ICs with on-board oscillators requiring low-frequency fundamental crystals are commonplace, but now IC frequency multipliers require the higher frequencies of third overtone crystals. Compared to its fundamental implementation however, the third-overtone (3OT) crystal oscillator is more complex, with different crystal characteristics plus additional reactive elements and higher gain. Most crystals use the fundamental thickness-shear vibration mode of AT-cut quartz. The practical upper limit of fundamental operation is around 50 MHz because the fundamental resonant frequency is inversely proportional to thickness. The 3OT is a crystal mode that resonates at three times its fundamental frequency. There are in fact an infinite number of odd harmonics that exist on the same quartz plate.


SAN JOSE, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, today announced that it has renewed a license agreement with LG Electronics, Inc., one of the world's largest providers of mobile devices. Building on an agreement the two companies signed in 2014, the new three-year extension provides a worldwide license for LG to use Immersion's TouchSense technology and Basic Haptics patents in its smartphones, tablets and fitness bands. Immersion's TouchSense technology enables device manufacturers to appeal to users' sense of touch by incorporating high-quality tactile effects and feedback in user interfaces and applications to simulate the connected experiences of the real world. With TouchSense technology, device manufacturers, app developers and UX designers can design high-quality, power-efficient tactile effects that enhance the user experience for mobile apps and device UI. “Haptics technology helps mobile OEMs differentiate their devices, making content more exciting and engaging for their customers. We look forward to continuing our work with LG, a valued partner that has shown how haptics creates an impactful mobile experience for consumers,” said Victor Viegas, President and CEO of Immersion. For mobile OEMs in the Android ecosystem, the TouchSense product family provides all it takes to design and implement the highest quality haptics across handset UI elements and apps: TouchSense 3000 is Immersion’s best-in-class end-to-end solution to design, enable, and optimize high-fidelity haptics in mobile handsets. The product package includes haptic software design tools and framework, reference guides, and on-site UX design services and FAE support, as well as intellectual property rights based on Immersion's comprehensive patent portfolio. TouchSense 3000 EES, another member of the TouchSense product family, offers similar benefits, but in addition has proprietary technology built in to particularly address the requirements of ERMs, which are among the most popular choices of actuator in the handset market. For a basic haptic experience, mobile OEMs can license the Basic Haptics patent portfolio and implement their own form of simple non-pressure related haptics, such as the non-pressure related haptics available in the Android OS. Immersion Corporation (NASDAQ: IMMR) is the leading innovator of touch feedback technology, also known as haptics. The company provides technology solutions for creating immersive and realistic experiences that enhance digital interactions by engaging users' sense of touch. With more than 2,300 issued or pending patents, Immersion's technology has been adopted in more than 3 billion digital devices, and provides haptics in mobile, automotive, advertising, gaming, medical and consumer electronics products. Immersion is headquartered in San Jose, California with offices worldwide. Learn more at www.immersion.com. This press release contains "forward-looking statements" that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Immersion Corporation and its consolidated subsidiaries to differ materially from those expressed or implied by such forward-looking statements. All statements, other than the statements of historical fact, are statements that may be deemed forward-looking statements, including, but not limited to, statements regarding the benefits of Immersion’s TouchSense technology, the continuing availability of LG’s mobile devices with Immersion’s TouchSense technology, and the future collaboration between Immersion and LG. Immersion's actual results might differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with Immersion's business, which include, but are not limited to: unanticipated difficulties and challenges encountered in product development efforts (including with respect to Immersion’s TouchSense Technology) by Immersion and its licensees; unanticipated difficulties and challenges encountered in implementation efforts by Immersion’s licensees; adverse outcomes in any future intellectual property-related litigation and the costs related thereto; the effects of the current macroeconomic climate; delay in or failure to achieve adoption of or commercial demand for Immersion's products or third party products incorporating Immersion's technologies; and lack of market demand for Immersion’s technologies. Many of these risks and uncertainties are beyond the control of Immersion. For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in Immersion's most current Form 10-K, and Form 10-Q, both of which are on file with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release reflect Immersion's beliefs and predictions as of the date of this release. Immersion disclaims any obligation to update these forward-looking statements as a result of financial, business, or any other developments occurring after the date of this release. Immersion, the Immersion logo, and TouchSense are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners.

Loading FAE collaborators
Loading FAE collaborators